Navigation Links
Anthera Provides Corporate Update on Recent Activities
Date:3/15/2012

HAYWARD, Calif., March 15, 2012 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today provided an update on company events following the recent termination of the VISTA-16 clinical study.

Immediately after the VISTA-16 Data Safety Monitoring Board (DSMB) recommended halting the clinical study, the Company took steps to cease patient enrollment and dosing. Redundant levels of written communication were sent to the investigators and clinical sites involved in the study to immediately cease enrollment and to withdraw all enrolled patients. The Company will be conducting final patient follow-up visits within the coming weeks.

The Company has taken immediate action to decrease operating expenses through a reduction or elimination of vendor activities and immediate headcount reductions. This will result in an elimination of approximately 45% of Anthera's headcount. These combined actions allow for the reallocation of resources to other potential development programs and product portfolio efforts.

Development of blisibimod (A-623) continues to progress according to plan. The PEARL-SC study, which completed enrollment in the fourth quarter of 2011, is examining the therapeutic benefit of monthly and weekly subcutaneous administration of blisibimod in SLE patients. The primary endpoint of the PEARL-SC study is clinical improvement at 24 weeks in an SLE responder index. The study remains on track to produce top-line efficacy data in the second quarter of 2012.

In addition, the PEARL-SC open-label extension (OLE) study continues to enroll patients. All patients who participated in the PEARL-SC study are eligible for rollover into the OLE clinical study.

About Anthera Pharmaceuticals

Anthera Pharmaceutica
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
2. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
3. Antheras A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
4. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
5. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
6. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
7. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
8. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
9. Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
10. Antheras Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
11. Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... -- Research and Markets ( http://www.researchandmarkets.com/research/tjlw9k/immunoprotein ) has ... Testing Market - Forecasts to 2019: Expected to ... is expected to be valued at USD 4,943.0 ... http://photos.prnewswire.com/prnh/20130307/600769 The ... according to immunoprotein types which include immunoglobulins, complement ...
(Date:7/10/2014)... , 11. Juli 2014  Dilon ... für die molekulare Bildgebung, einschließlich molekularer ... die CE-Zulassung für sein Navigator ® ... Dilon das Produkt jetzt europaweit vertreiben. ... Großteil der europäischen Länder ausgedehnt und ...
(Date:7/10/2014)... 10, 2014 Yesterday, former Congressman ... device manufacturing facility. Rep. Kennedy and Dick ... facilitate cutting-edge research in neurological disease and treatment. ... health advocate, Garen Staglin , created One ... fundamental changes that will radically accelerate the development ...
Breaking Medicine Technology:Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2
... Reportlinker.com announces that a new market ... Respiratory Devices - Global ... to 2016 http://www.reportlinker.com/p0240243/Respiratory-Devices---Global-Pipeline-Analysis-Opportunity-Assessment-and-Market-Forecasts-to-2016.html ... Global Pipeline Analysis, Opportunity Assessment and Market ...
... 14 AAIPharma Services Corp., a leading provider of ... announced today that it has appointed Patrick D. Walsh ... equity firm focused exclusively on health care that acquired ... company in 2009, was instrumental in recruiting Mr. Walsh ...
Cached Medicine Technology:Reportlinker Adds Respiratory Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 2Reportlinker Adds Respiratory Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 3AAIPharma Services Corp. Names Patrick Walsh Chief Executive Officer 2AAIPharma Services Corp. Names Patrick Walsh Chief Executive Officer 3
(Date:7/12/2014)... The largest pure occupational medicine company in the ... it will be opening its fifth Georgia center in ... Atlanta-based Nova Medical Centers’ locations. The Augusta facility ... and will be open from 8:30 a.m. to 6 ... philosophy of rapid return-to-work and decreased treatment times for ...
(Date:7/11/2014)... 2014 Recently, DressyQuinceanera.com, a well-known wedding ... Dama dresses to its online category. Furthermore, the ... at deeply discounted rates, up to 62% off. , ... equally excellent in terms of quality and style. All ... discounts are also offered for the company’s other items: ...
(Date:7/11/2014)... Ticket Down reports that tickets to the Argentina ... Cup Match between Brazil and Netherlands are in ... Saturday, July 12th at Estadio Nacional de Brasilia Mane Garrincha ... on Sunday, July 13th at Estadio Jornalista Mario Filho - ... 2014 World Cup are guaranteed to be authentic and are ...
(Date:7/11/2014)... 2014 (HealthDay News) -- Reducing the number of deer ... Lyme disease and other tick-borne infections among people, new ... can be manipulated to reduce human interactions with deer, ... disease," the researchers wrote. White-tailed deer are the ... disease to people. The study included nearly all ...
(Date:7/11/2014)... Volunteers from Scientology Churches and ... with drug education lectures, forums and conferences, information stands, ... around the world. , Drug abuse is an international ... Abuse, abuse of alcohol and illicit drugs costs more ... decreased productivity and healthcare. , In the face ...
Breaking Medicine News(10 mins):Health News:Nova Medical Centers To Open New Facility in Augusta, Georgia 2Health News:DressyQuinceanera.com: Beautiful Quinceanera Dama Dresses At Low Prices 2Health News:Argentina vs. Germany World Cup Finals Tickets & Brazil vs. Netherlands 3rd Place World Cup Tickets Are in Huge Demand 2Health News:Scientologists Taking Action against Drug Abuse 2Health News:Scientologists Taking Action against Drug Abuse 3
... Bisphenol A (BPA) is used in the manufacture of plastics ... a tendency to become highly unstable due to break in ... container causing damage to human health. BPA is found to ... and developmental problems. Estrogens is a female sex hormone which ...
... brings joy and excitement to the parents and family members ... birth of baby Maia, after her mother successfully// underwent radiotherapy ... anything come between her baby and self. ... and was staged III Hodgkin’s lymphoma. She was required to ...
... camp is further complicating the relief efforts taken by ... cases have been reported, with the death of a ... of them are children and under surveillance," said Abdul ... said eight of the infected children had already been ...
... Mothers have been known to influence their children in ... been found that their attitude towards eating habits and ... teenagers as well. Perception of the teenager’s mother regarding ... ,A number of genetic and other environmental factors are ...
... being sold to foreigners for human transplantation purposes in ... officials, who have been passive// about the issue for ... of such an inhuman act. ,Despite reports ... strangers (were paid for their donation) and transmission of ...
... to the press about improvising the health care facilities at ... needs more hospitals with ICUs// and ambulance facilities 24-hour health ... , ,He put forth the idea about giving ... authorities. He also mentioned that the chief minister Mr. Nitish ...
Cached Medicine News:Health News:Robotic ovarian transposition helps cancer patient deliver baby 2Health News:Adolescents Influenced By Maternal Attitude Regarding Weight Control 2Health News:Widespread Commercialisation Of Human Organ Donation In China 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: